<DOC>
	<DOCNO>NCT00427128</DOCNO>
	<brief_summary>This study randomize two stratification acute phase MDD SSRI responder , categorize either `` true drug '' response `` placebo response '' pattern , continuation SSRI v placebo double-blind trial determine stratification category predict continuation outcome .</brief_summary>
	<brief_title>Prozac Treatment Major Depression : Discontinuation Study</brief_title>
	<detailed_description>This study enrol 627 subject Major Depressive illness New York State Psychiatric Institute Massachusetts General Hospital . Subjects treat fluoxetine 10-60mg 12 week period . The `` responder '' group define longer meet criterion Major Depression week 12 , along CGI rating `` much improve '' `` much improve '' determine independent evaluator . At week 12 `` non-responders '' withdrawn study receive open label treatment ; responder randomize double-blind fashion either fluoxetine continuation ( 20-80mg daily ) response dose placebo switch 24 week . The responder group stratify `` specific true '' drug response ( late onset persistent attain ) `` nonspecific placebo '' response ( early onset nonpersistent ) pattern . Subjects evaluate one week two week interval different phase continuation treatment , depression relapse determine agreement study psychiatrist independent evaluator CGI Ham-D rating , well administration MDD section Mood Disorders Module Structured Clinical Interview DSM-IV Disorders visit . A subset study participant also provide DNA sample determine whether DNA marker response type . Data analyze test follow hypothesis : continuation fluoxetine treatment improve patient `` true drug '' acute response pattern randomize placebo poorer outcome maintain active drug ; continuation fluoxetine treatment improve patient `` placebo '' acute response pattern randomize placebo bad outcome maintain drug ; continuation fluoxetine treatment patient `` true drug '' acute response pattern randomize continue fluoxetine likely maintain benefit `` placebo '' pattern .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>1. men woman age 1865 2. meet criteria DSM IV Major Depression 3. sign informed consent able comply study 1. pregnant woman woman childbearing potential use medically accept mean contraception . 2. woman take oral contraceptive , initiation temporally associate onset depression ; woman breastfeed . 3 . Patients serious suicidal risk , include patient become suicidal previous discontinuation antidepressant . 4 . Patients history seizure disorder . 5 . Patients unstable physical disorder ( cardiovascular , hepatic , renal , respiratory , endocrine , neurologic , hematologic ) physical disorder judge significantly affect CNS function . 6 . Patients meet criterion follow DSMIV diagnosis : organic mental disorder ; substance use disorder , include alcohol , active within last 6 month ; schizophrenia ; delusional disorder ; psychotic disorder ; bipolar disorder ; antisocial personality disorder ; presence psychotic feature 7 . Patients history nonresponse adequate trial selective serotonin reuptake inhibitor past current depressive episode , define fourweek trial minimum 40mg/day fluoxetine paroxetine , 100mg/day sertraline . 8 . Concurrent use exclusionary drug 9 . Clinical laboratory evidence hypothyroidism without adequate stable replacement ( eg , low total T4 elevate TSH high sensitivity method ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Major Depression</keyword>
	<keyword>`` true drug '' response</keyword>
	<keyword>`` placebo response '' pattern</keyword>
	<keyword>continuation treatment outcome</keyword>
</DOC>